309例经皮质入路清醒手术治疗累及岛叶的IDH突变低级别胶质瘤:253例连续患者的长期肿瘤与功能结局
该研究纳入2002年6月至2024年1月由同一术者经岛盖入路行清醒手术功能定位切除的岛叶IDH突变2级胶质瘤患者,共253例、309次手术,比较纯岛叶胶质瘤(1组39例)与岛叶为中心并累及额和/或颞和/或顶叶的胶质瘤(2组214例)的长期肿瘤与功能结局。结果显示两组切除程度与术后难治性癫痫率相似,2组恢复工作比例更高,总体功能保留与生存率较高。
要点
- 253例岛叶IDH突变2级胶质瘤患者共行309次清醒手术,平均随访7.1±3.9年,总体生存率80.2%。
- 仅2例(99.2%)出现永久性术后神经功能缺损,199例恢复工作(96.6%)。
- 2组术前难治性癫痫率及肿瘤体积高于1组,但两组切除程度与术后难治性癫痫率相似。
核心结论
- 这是目前最大宗的经岛盖入路基于清醒定位切除累及岛叶低级别胶质瘤的同质化手术经验。
- 结果显示功能保留与恢复工作比例高,总体生存率高。
研究设计与样本
- 回顾性单术者连续队列,纳入2002年6月至2024年1月经岛盖入路行清醒手术功能定位切除的岛叶IDH突变2级胶质瘤患者。
- 共253例患者、309次清醒手术,按肿瘤累及范围分为纯岛叶胶质瘤组(1组39例肿瘤,15.4%)与岛叶为中心并累及额和/或颞和/或顶叶组(2组214例肿瘤,84.6%)。
主要发现
- 253例患者中男性132例(52.2%),平均年龄37.5±9.5岁;术前214例(84.5%)有癫痫,其中55例为药物难治性癫痫(21.7%)。
- 术前平均Karnofsky功能状态评分93.1±7.4,206例(81.4%)术前在工作;左侧胶质瘤147例(58.1%)。
- 平均术前肿瘤体积70.1±50.1 cm3;平均切除程度89.4%±8.4%,平均残余肿瘤体积9.6±13.1 cm3。
- 病理为星形细胞瘤166例(65.6%)、少突胶质细胞瘤87例(34.4%);53例(20.9%)术后即刻接受辅助治疗,49例(19.3%)后续再次行清醒手术。
- 平均随访7.1±3.9年,总体生存率80.2%(末次评估时203例仍存活);除2例外(99.2%)无永久性术后神经功能缺损,术后平均Karnofsky功能状态评分93±6.6,199例恢复工作(96.6%),仅20例(7.9%)仍有难治性癫痫。
关键数值与推荐
- 1组意外发现胶质瘤比例高于2组(p=0.00009)。
- 2组术前难治性癫痫率高于1组(p=0.0019),术前肿瘤体积大于1组(p<0.00001)。
- 两组切除程度与术后难治性癫痫率相似,2组恢复工作比例高于1组(p=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In low-grade glioma (LGG), awake surgery (AS) with intraoperative functional mapping minimizes morbidity while increasing the extent of resection (EOR). However, the actual role of AS for insular LGG resection through the opercula is still debated. The aim of this study was to investigate the long-term results after AS via a transcortical approach in patients with LGG within the insula, and to compare outcomes between pure insular gliomas and gliomas also invading other lobes. METHODS: Patients who underwent AS with functional-based resection via the opercula performed by the author for an isocitrate dehydrogenase-mutant grade 2 glioma involving the insula were selected (June 2002-January 2024). Functional and oncological outcomes were analyzed by comparing pure insular gliomas (group 1) versus insular-centered gliomas also involving the frontal and/or temporal and/or parietal lobes (group 2). RESULTS: In this consecutive cohort, 309 ASs were achieved in 253 patients (132 men [52.2%], mean age 37.5 ± 9.5 years). Among 214 patients (84.5%) with epilepsy before surgery, 55 had intractable seizures (21.7%). The preoperative mean Karnofsky Performance Scale score was 93.1 ± 7.4, with 206 patients (81.4%) working before surgery. The series included 147 left-sided gliomas (58.1%), with a mean preoperative tumor volume for both sides of 70.1 ± 50.1 cm3 with 39 total tumors (15.4%) in group 1 and 214 total tumors (84.6%) in group 2. No patients except 2 (99.2%) had a permanent postoperative deficit (mean Karnofsky Performance Scale score 93 ± 6.6), with 199 patients returning to work (96.6%). Only 20 patients (7.9%) continued to suffer from intractable epilepsy. The mean EOR was 89.4% ± 8.4% (mean residual tumor volume: 9.6 ± 13.1 cm3). There were 166 astrocytomas (65.6%) and 87 oligodendrogliomas (34.4%). Fifty-three patients (20.9%) received immediate postoperative adjuvant therapy and 49 patients (19.3%) underwent subsequent AS. The mean follow-up was 7.1 ± 3.9 years, with an overall survival rate of 80.2% (203 patients were still alive at last evaluation). More patients had an incidental glioma in group 1 (p = 0.00009), whereas there was a higher rate of intractable seizures (p = 0.0019) and a greater tumor volume before surgery in group 2 (p < 0.00001). Nonetheless, the EOR and the rate of postoperative intractable seizures were similar in both groups, with more patients in group 2 resuming work (p = 0.001). CONCLUSIONS: This is the largest homogeneous surgical experience of LGGs involving the insula that were resected through the opercula based on awake mapping. The results show a high percentage of functional preservation and return to work, with a high overall survival rate.
引用
- Duffau H. A series of 309 awake surgeries with transcortical approach for IDH-mutant low-grade glioma involving the insula: long-term onco-functional outcomes in 253 consecutive patients. J Neurosurg. 2025. PMID: 40250045. doi:10.3171/2025.1.JNS242462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。